Combination of Trastuzumab Emtansine and Stereotactic Radiosurgery Results in High Rates of Clinically Significant Radionecrosis and Dysregulation of Aquaporin-4
Abstract
Patients with human EGFR2-positive (HER2+) breast cancer have a high incidence of brain metastases, and trastuzumab emtansine (T-DM1) is often employed. Stereotactic radiosurgery (SRS) is frequently utilized, and case series report increased toxicity with combination SRS and T-DM1. We provide an update of our experience of T-DM1 and SRS evaluating risk of clinically significant radionecrosis (CSRN) and propose a mechanism for this toxicity.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jul 01, 2019
- Source ID
- 10.1158/1078-0432.ccr-18-2851
Entities
People
- Arthur Liu
- Brian D. Kavanagh
- Chad G. Rusthoven
- Christine M. Fisher
- D. Ryan Ormond
- Diana M Cittelly
- Jennifer R. Diamond
- Julie A. Carlson
- Kelly A. Stuhr
- Laurie E. Gaspar
- María J Contreras-Zárate
- Peter Kabos
- Priscilla K. Stumpf
- Rachel Rabinovitch
- Steven Lai
- Tyler P Robin
Organizations
- National Cancer Institute
- United States Department of Defense
- University of Colorado
- University of Colorado School of Medicine